Skip to content
Tenfell
Awarded contract
Published 14 Aug 2015

Provision of over-encapsulated Sitagliptin (Januvia), Pioglitazone (Actos) and Cangliflozin (Invokana) for a double-blind randomised clinical trial

University of Exeter · South West

Key facts

Contract value
£528,571
Awarded
13 Sep 2015
Contract starts
21 Sep 2015
Contract ends
31 Jul 2019
Procedure
Open procedure
Buyer type
Education

Awarded to

SupplierValue
Tayside Pharmaceuticals£528,571

Description

The University of Exeter is seeking a suitable and capable provider of investigational medicinal product for use by its Medical School as part of a diabetes clinical trial. The Unviersity of Exeter Medical School is undertaking a MRC-funded study aiming to develop a stratified approach in Type 2 diabetes that will result in more effective use of glucose lowering therapy. The Trimaster trial, sponsored by the Royal Devon & Exeter NHS Foundation Trust (RD&E FT) is a randomised double-blind Cross-Over trial of three standard diabetes therapies, a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in 600 patients with type 2 diabetes. It aims to directly test potential stratification by comparing a patient’s response (in terms of glycaemia, weight change, hypoglycaemia and patient reported outcomes) to these three glucose-lowering treatments.

Categories (CPV)

Similar open tenders

About University of Exeter

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.